PMGC Holdings (ELAB) risk factors, FY2024 10-K

Risks Related to Our Financial Condition

1. 01Our financial statements have been prepared on a going-concern basis and our continued operations are in doubt
2. 02We have a history of net losses, and we may not be able to achieve or maintain profitability in the future
3. 03Our current growth may not be indicative of our future growth and, if we begin to grow rapidly, we may not be able to effectively manage our growth or evaluate our future prospects. If we fail to effectively manage our future growth or evaluate our future prospects, our business could be adversely affected
4. 04We will need additional capital to conduct our operations and develop our products and our ability to obtain the necessary funding is uncertain

Risks Related to Our Business, Our Portfolio Companies, and the Biotechnology Industry

1. 05Our acquired technologies and products under development could be rendered obsolete by technological, regulatory, or medical advances
2. 06To sustain our continued growth, we will need to increase the size of our organization, and we may encounter difficulties managing our growth, which could adversely affect our results of operations
3. 07If we are unable to secure strategic commercial partnerships, licensing agreements, funding, or other key business relationships following successful clinical results, our revenue potential may be limited
4. 08Potential business combinations and licensing agreements could require significant management attention and prove difficult to integrate, which could divert attention away from management, disrupt our normal course of business, dilute stockholder value, and adversely affect our operating results
5. 09If we fail to cost-effectively acquire, license, or develop biotechnology assets, our business could be adversely affected
6. 10If we fail to secure strategic partnerships or commercialization agreements, our revenue potential may be limited
7. 11Our brand and reputation may be diminished due to intellectual property disputes, perceived scientific failures, or negative publicity, which could have an adverse effect on our business
8. 12Economic downturns, shifts in healthcare investment trends, regulatory changes, and evolving market demand for biotechnology products could negatively affect our business
9. 13If we cannot maintain our company culture or focus on our strategic mission as we grow, our success and competitive position may be harmed
10. 14If we lose key personnel or are unable to attract and retain other qualified personnel, we may be unable to execute our business plan, and our business could be materially adversely affected
11. 15We may be unable to accurately forecast revenue and appropriately plan our expenses in the future
12. 16We have a limited operating history at our current scale, which may make it difficult to evaluate our business and future prospects
13. 17A disruption in our operations could have an adverse effect on our business
14. 18Our business is at an early stage of asset development, and we may not successfully develop, License, or commercialize biotechnology assets
15. 19Uncertainty in market demand, regulatory approval, and investment cycles could impact our future growth
16. 20We may incur product liability or intellectual property claims that could harm our business
17. 21There is a risk that our insurance policies and our portfolio companies’ insurance policies are inadequate to cover liabilities
18. 22We face additional business risks through our multi-strategy investment vehicle, PMGC Capital LLC, which risks may adversely impact our financial performance
19. 23Our employees, independent contractors, consultants, strategic partners, and third parties may engage in unethical misconduct, regulatory noncompliance, or other improper activities that could harm our business
20. 24Our portfolio companies’ products and technologies may fail to achieve the broad adoption necessary for commercial success, which may negatively impact our financial performance
21. 25The outcome of clinical and product testing for our portfolio companies is uncertain
22. 26Even if our portfolio companies’ technologies are successful, rapid advancements in biotechnology could make them obsolete
23. 27Biotechnology products often require complex, costly manufacturing processes. If our portfolio companies fail to optimize production, scale efficiently, or negotiate favorable supply chain agreements, their profit margins may be significantly lower than competing therapies
24. 28Evolving regulations governing biotechnology, pharmaceuticals, and investments could negatively impact our business
25. 29Government regulations and private party actions relating to the marketing and advertising of biotechnology and pharmaceutical products may restrict, inhibit, or delay commercialization efforts
26. 30The development and acquisition of therapeutic product candidates could expose us to significant legal and regulatory risks
27. 31We license from a third party the rights to product candidates related to the potential prevention and treatment of muscular and obesity-related conditions, and are therefore subject to the risk that we lose the license after investing substantial resources into the research and development of these product candidates
28. 32Because our future commercial success with respect to the Licensed Products depends on gaining regulatory approval for our products, we cannot generate revenue without obtaining approvals
29. 33We expect to invest material efforts and financial resources in the development of the Licensed Products. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of the Licensed Products
30. 34The Licensed Products may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance
31. 35Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to the Licensed Products which may force us to terminate our research efforts of one or more product candidates
32. 36The divestiture of our Elevai Skincare business could negatively impact our operations and strategic positioning
33. 37International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could adversely impact our business
34. 38Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations
35. 39Regulatory changes or actions may alter the nature of an investment in us or restrict the use of cryptocurrencies in a manner that adversely affects our business, prospects, or operations
36. 40Our business, operations, financial position and clinical development plans and timelines, could be materially adversely affected by the continuing military action in Ukraine and the war between Israel and Hamas

Risks Related to Our Dependence on Third Parties

1. 41We depend on our collaborators to help us develop and test our proposed products, and our ability to develop and commercialize products may be impaired or delayed if collaborations are unsuccessful
2. 42Our reliance on the activities of our non-employee consultants, third-party vendors, and operational contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products
3. 43We or our third-party vendors may experience in the future network or system failures, or service interruptions, including cybersecurity attacks, or other technology risks. Our inability to protect our systems and data against such risks could harm our business and reputation
4. 44Although we have not experienced any security breaches or attempted security breaches and continue to invest in security measures, we cannot be certain that our defensive measures, and those employed by our third-party vendors, will be sufficient to defend against all such current and future methods
5. 45Our business could be negatively impacted by cybersecurity threats and other security threats and disruptions
6. 46If our third-party suppliers, logistics, and manufacturers do not comply with ethical business practices or with applicable laws and regulations, our reputation, business, financial condition, results of operations and prospects could be harmed
7. 47If we, or our third-party manufacturers fail to comply with environmental laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

Risks Related to Our Intellectual Property

1. 48If we fail to protect or enforce our intellectual property or confidential proprietary information relating to our current and any future medical aesthetics products or medical aesthetics pipeline product, others could compete against us more directly and we may not be able to compete effectively in our market
2. 49Certain of our technology may not be subject to protection through patents, which leaves us vulnerable to theft of our technology
3. 50We may not be able to protect our proprietary technology, which could harm our ability to operate profitably
4. 51If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our target markets and our business may be adversely affected
5. 52If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed
6. 53We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
7. 54We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms

Risks Related to Our Capital Requirements and Finances

1. 55If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize our products

Risks Related to the Ownership of Our Securities

1. 56The price of our Common Stock may be adversely affected by the future issuance and sale of shares of our Common Stock or other equity securities
2. 57Future sales by stockholders, or the perception that such sales may occur, may depress the price of our Common Stock
3. 58The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing stockholders
4. 59Our Common Stock may be affected by limited trading volume and price fluctuations, which could adversely impact the value of our Common Stock
5. 60Our Common Stock is currently listed on Nasdaq and we must meet certain financial and liquidity criteria to maintain such listing. If we violate the maintenance requirements for continued listing of our Common Stock, our Common Stock may be delisted
6. 61We currently do not intend to declare dividends on our Common Stock in the foreseeable future and, as a result, your returns on your investment may depend solely on the appreciation of our Common Stock
7. 62An investment in our securities is speculative and there can be no assurance of any return on any such investment
8. 63We may need, but be unable, to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose burdensome financial restrictions on our business
9. 64The requirements of being a public company may strain our resources, divert management’s attention and affect our results of operations
10. 65New laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming
11. 66If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
12. 67If there is no active public market for our Common Stock, you may be unable to sell your shares at or above your purchase price
13. 68We may be subject to securities litigation, which is expensive and could divert our management’s attention